P
Paul A. Brogan
Researcher at UCL Institute of Child Health
Publications - 271
Citations - 10989
Paul A. Brogan is an academic researcher from UCL Institute of Child Health. The author has contributed to research in topics: Vasculitis & Systemic vasculitis. The author has an hindex of 50, co-authored 247 publications receiving 8577 citations. Previous affiliations of Paul A. Brogan include Charles University in Prague & Hacettepe University.
Papers
More filters
Journal ArticleDOI
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Gillian I. Rice,Paul R. Kasher,Gabriella Forte,Niamh M. Mannion,Sam M. Greenwood,Marcin Szynkiewicz,Jonathan E. Dickerson,Sanjeev S. Bhaskar,Massimiliano Zampini,Tracy A Briggs,Emma M. Jenkinson,Carlos A. Bacino,Roberta Battini,Enrico Bertini,Paul A. Brogan,Louise Brueton,Marialuisa Carpanelli,Corinne De Laet,Pascale de Lonlay,Mireia Del Toro,Isabelle Desguerre,Elisa Fazzi,Angels García-Cazorla,Arvid Heiberg,Masakazu Kawaguchi,Ram L. Kumar,Jean-Pierre Lin,Charles Marques Lourenço,Alison Male,Wilson Marques,Cyril Mignot,Ivana Olivieri,Simona Orcesi,Prab Prabhakar,Magnhild Rasmussen,Robert Robinson,Flore Rozenberg,Johanna L. Schmidt,Katharina Steindl,Tiong Yang Tan,William G. Van Der Merwe,Adeline Vanderver,Grace Vassallo,Emma Wakeling,Evangeline Wassmer,Elizabeth Whittaker,John H. Livingston,Pierre Lebon,Tamio Suzuki,Paul J. McLaughlin,Liam Keegan,Mary A O'Connell,Simon C. Lovell,Yanick J. Crow +53 more
TL;DR: It is shown that mutations in ADAR1 cause the autoimmune disorder Aicardi-Goutières syndrome (AGS), and it is speculated that ADar1 may limit the cytoplasmic accumulation of the dsRNA generated from genomic repetitive elements.
Journal ArticleDOI
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez,Adam L Reinhardt,Suzanne E. Ramsey,Helmut Wittkowski,Philip J. Hashkes,Yackov Berkun,Susanne Schalm,Sara Murias,Jason Dare,Diane Brown,Deborah L. Stone,Ling Gao,Thomas Klausmeier,Dirk Foell,Adriana Almeida de Jesus,Dawn Chapelle,Hanna Kim,Samantha Dill,Robert A. Colbert,Laura Failla,B. Kost,Michelle O'Brien,James C. Reynolds,Les R. Folio,Katherine R. Calvo,Scott M. Paul,Nargues Weir,Alessandra Brofferio,Ariane Soldatos,Angelique Biancotto,Edward W. Cowen,John J. Digiovanna,Massimo Gadina,Andrew Lipton,Colleen Hadigan,Steven M. Holland,Joseph A. Fontana,Ahmad Samer Alawad,Rebecca J. Brown,Kristina I. Rother,Theo Heller,Kristina M Brooks,Parag Kumar,Stephen R. Brooks,Meryl Waldman,Harsharan K. Singh,Volker Nickeleit,Maria Silk,Apurva Prakash,Jonathan Janes,Seza Ozen,Paul G. Wakim,Paul A. Brogan,William L. Macias,Raphaela Goldbach-Mansky +54 more
TL;DR: Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interfer onopathies.
Journal ArticleDOI
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
Rachel B Jones,Alastair J. Ferraro,Afzal N. Chaudhry,Paul A. Brogan,Alan D. Salama,Kenneth G. C. Smith,Caroline O. S. Savage,David Jayne +7 more
TL;DR: Rituximab was effective remission induction therapy for refractory ANCA-associated vasculitis in this study and there was no difference in efficacy between the 2 main treatment regimens.
Journal ArticleDOI
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.
Chiea Chuen Khor,Chiea Chuen Khor,Sonia Davila,Sonia Davila,Willemijn B. Breunis,Yi-Ching Lee,Chisato Shimizu,Chisato Shimizu,Victoria J. Wright,Rae S. M. Yeung,Dennis E.K. Tan,Kar Seng Sim,Jie Jin Wang,Jie Jin Wang,Tien Yin Wong,Tien Yin Wong,Tien Yin Wong,Junxiong Pang,Junxiong Pang,Paul Mitchell,Rolando Cimaz,Nagib Dahdah,Yiu-fai Cheung,Guo Ying Huang,Wanling Yang,In Sook Park,Jong-Keuk Lee,Jer-Yuarn Wu,Michael Levin,Jane C. Burns,Jane C. Burns,David Burgner,David Burgner,Taco W. Kuijpers,Martin L. Hibberd,Martin L. Hibberd,Yu-Lung Lau,Jing Zhang,Xiao Jing Ma,Fang Liu,Lin Wu,Jeong Jin Yoo,Soo-Jong Hong,Kwi Joo Kim,Jae-Jung Kim,Young-Mi Park,Young Mi Hong,Sejung Sohn,Gi Young Jang,Kee Soo Ha,Hyo Kyoung Nam,Jung Hye Byeon,Sin Weon Yun,Myung Ki Han,Kyung-Yil Lee,Ja Young Hwang,Jung Woo Rhim,Min Seob Song,Hyoung Doo Lee,Dong Soo Kim,Jae Moo Lee,Jeng Sheng Chang,Fuu Jen Tsai,Chi Di Liang,Ming-Ren Chen,Hsin Chi,Nan Chang Chiu,Fu Yuan Huang,Luan-Yin Chang,Li-Min Huang,Ho-Chang Kuo,Kao Pin Huang,Meng Luen Lee,Betau Hwang,Yhu Chering Huang,Pi Chang Lee,Miranda Odam,Miranda Odam,Frank T. Christiansen,Campbell S. Witt,Paul N. Goldwater,Paul N. Goldwater,Nigel Curtis,Nigel Curtis,Pamela Palasanthiran,John B. Ziegler,Michael D. Nissen,Clare Nourse,Irene M. Kuipers,J Ottenkamp,Judy Geissler,Maarten H Biezeveld,Carline E. Tacke,Luc Filippini,Paul A. Brogan,Nigel Klein,Vanita Shah,M J Dillon,Robert Booy,Delane Shingadia,Anu Bose,Thomas Mukasa,Robert Tulloh,Colin Michie,Jane W. Newburger,Annette L. Baker,Anne H. Rowley,Stanford T. Shulman,Wilbert H. Mason,Masato Takahashi,Marian E. Melish,Adriana H. Tremoulet,Ananth C. Viswanathan,Elena Rochtchina,John Attia,Rodney J. Scott,Elizabeth G. Holliday,Stephen B. Harrap +117 more
TL;DR: The involvement of the FCGR2A locus may have implications for understanding immune activation in Kawasaki disease pathogenesis and the mechanism of response to intravenous immunoglobulin, the only proven therapy for this disease.
Journal ArticleDOI
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
Fabrizio De Benedetti,Marco Gattorno,Jordi Anton,Eldad Ben-Chetrit,Joost Frenkel,Hal M. Hoffman,Isabelle Koné-Paut,Helen J. Lachmann,Seza Ozen,Anna Simon,Andrew Zeft,Inmaculada Calvo Penades,Michel Moutschen,Pierre Quartier,Ozgur Kasapcopur,Anna Shcherbina,Michael Hofer,Philip J. Hashkes,Jeroen Van der Hilst,Ryoki Hara,Segundo Bujan-Rivas,Tamás Constantin,Ahmet Gül,Avi Livneh,Paul A. Brogan,Marco Cattalini,Laura Obici,Karine Lheritier,A. Speziale,Guido Junge +29 more
TL;DR: In this trial, canakinumab was effective in controlling and preventing flares in patients with colchicine‐resistant familial Mediterranean fever, mevalonate kinase deficiency, and TRAPS.